Understanding the actions and interactions of ovarian steroids (estradiol and progesterone) and the tumor repressor protein (TRP53, TP53) becomes of utmost clinical relevance when epithelial cells undergo oncogenic transformation to form cancers. Ovarian (epithelial) cancer is of paramount importance because this disease is the fifth most lethal cause of death in women and, with more than 14,000 deaths annually, remains an ominous threat to women's health. Clinical and epidemiological data show a strong link between ovarian steroids and ovarian cancer; ~90% of ovarian cancers harbor mutations in TP53. Unfortunately, little is known about the molecular mechanisms by which TP53 status and steroids impact ovarian cancer tumor progression and metastasis. We have generated unique mouse models that will allow us to define the actions of estradiol on ovarian epithelial cell cancer in vivo. Based on provocative observations in these mice, we hypothesize that increased expression of ER??and estrogen-induced genes mediate ovarian cancer tumor growth and metastasis in ovarian cancers lacking functional TRP53 (tumor repressor protein 53 or p53) or expressing mutant TRP53. These powerful mouse models combined with human ovarian cancer cell lines will allow us to determine for the first time: 1) how steroids control ovarian cancer cell progression and metastasis in vivo; 2) which specific genes are targets of estrogen in the transformed cells in vivo and 3) if intercepting these pathways by progesterone or estrogen receptor antagonists blocks metastasis or tumor growth and 4) how estradiol alters the metastatic sites. To address these goals we propose the following specific aims.
Specific Aim 1 : Determine the molecular mechanisms by which TRP53 and estradiol impact ovarian tumor progression and metastasis in vivo.
Specific Aim 2 : Determine the impact of mutant TRP53(R172H) on hormone-regulated ovarian tumor progression and metastasis in vivo.
Specific Aim 3 : Determine if metastatic tumor growth involves TRP53 status and steroid action in peritoneal cells.
The steroid hormones (estrogens and progesterone) impact incidence and risk of ovarian epithelial cell cancer in women. Unfortunately, little is known about how they regulate ovarian tumor growth and metastases. Our unique mouse models will allow us to define for the first time the actions and target genes of estrogens at early stages of ovaria epithelial cell cancer in vivo, providing insights relevant to this cancer in women.
|Padmanabhan, Achuth; Candelaria, Nicholes; Wong, Kwong-Kwok et al. (2018) USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun 9:1270|
|Kawai, Tomoko; Richards, JoAnne S; Shimada, Masayuki (2018) The Cell Type-Specific Expression of Lhcgr in Mouse Ovarian Cells: Evidence for a DNA-Demethylation-Dependent Mechanism. Endocrinology 159:2062-2074|
|Ren, Yi A; Mullany, Lisa K; Liu, Zhilin et al. (2016) Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. Cancer Res 76:2206-18|
|Ren, Yi A; Liu, Zhilin; Mullany, Lisa K et al. (2016) Growth Arrest Specific-1 (GAS1) Is a C/EBP Target Gene That Functions in Ovulation and Corpus Luteum Formation in Mice. Biol Reprod 94:44|
|Adams, Jaye; Liu, Zhilin; Ren, Yi Athena et al. (2016) Enhanced Inflammatory Transcriptome in the Granulosa Cells of Women With Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 101:3459-68|
|Rodriguez, Amanda; Pangas, Stephanie A (2016) Regulation of germ cell function by SUMOylation. Cell Tissue Res 363:47-55|
|Crane, Erin K; Kwan, Suet-Yan; Izaguirre, Daisy I et al. (2015) Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One 10:e0135101|
|Mullany, Lisa K; Wong, Kwong-Kwok; Marciano, David C et al. (2015) Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia 17:789-803|